Literature DB >> 22513313

Clopidogrel: a case for indication-specific pharmacogenetics.

J A Johnson1, D M Roden, L J Lesko, E Ashley, T E Klein, A R Shuldiner.   

Abstract

The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22513313      PMCID： PMC3382015          DOI： 10.1038/clpt.2012.21

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  10 in total

1.  Pharmacogenomics and clopidogrel: irrational exuberance?

Authors:  Steven E Nissen
Journal:  JAMA       Date:  2011-12-28       Impact factor: 56.272

2.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

Authors:  Guillaume Paré; Shamir R Mehta; Salim Yusuf; Sonia S Anand; Stuart J Connolly; Jack Hirsh; Katy Simonsen; Deepak L Bhatt; Keith A A Fox; John W Eikelboom
Journal:  N Engl J Med       Date:  2010-08-29       Impact factor: 91.245

3.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

Review 4.  CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Authors:  Michael V Holmes; Pablo Perel; Tina Shah; Aroon D Hingorani; Juan P Casas
Journal:  JAMA       Date:  2011-12-28       Impact factor: 56.272

5.  Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.

Authors:  Jean-Sébastien Hulot; Jean-Philippe Collet; Johanne Silvain; Ana Pena; Anne Bellemain-Appaix; Olivier Barthélémy; Guillaume Cayla; Farzin Beygui; Gilles Montalescot
Journal:  J Am Coll Cardiol       Date:  2010-07-06       Impact factor: 24.094

6.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Authors:  Jean-Sébastien Hulot; Alessandra Bura; Eric Villard; Michel Azizi; Véronique Remones; Catherine Goyenvalle; Martine Aiach; Philippe Lechat; Pascale Gaussem
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

Review 7.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Authors:  S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

8.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

9.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

Review 10.  Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Authors:  Tim Bauer; Heleen J Bouman; Jochem W van Werkum; Neville F Ford; Jurriën M ten Berg; Dirk Taubert
Journal:  BMJ       Date:  2011-08-04
  10 in total
  38 in total

Review 1.  CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis.

Authors:  Xuan Niu; Ling Mao; Yan Huang; Suraj Baral; Jian-Yong Li; Yuan Gao; Yuan-Peng Xia; Quan-Wei He; Meng-Die Wang; Man Li; Li Zou; Xiao-Ping Miao; Bo Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

Review 2.  Antiplatelet drug interactions with proton pump inhibitors.

Authors:  Stuart A Scott; Aniwaa Owusu Obeng; Jean-Sébastien Hulot
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-11-09       Impact factor: 4.481

Review 3.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

Review 4.  Cardiovascular pharmacogenomics: current status and future directions.

Authors:  Dan M Roden
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

Review 5.  Applied pharmacogenomics in cardiovascular medicine.

Authors:  Peter Weeke; Dan M Roden
Journal:  Annu Rev Med       Date:  2013-10-02       Impact factor: 13.739

Review 6.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

7.  Drug-gene interactions: inherent variability in drug maintenance dose requirements.

Authors:  Paul Westervelt; Kihoon Cho; David R Bright; David F Kisor
Journal:  P T       Date:  2014-09

Review 8.  Towards precision medicine.

Authors:  Euan A Ashley
Journal:  Nat Rev Genet       Date:  2016-08-16       Impact factor: 53.242

Review 9.  Personalized medicine: Genetic risk prediction of drug response.

Authors:  Ge Zhang; Daniel W Nebert
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 10.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.